New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
11:58 EDTALNYAlnylam updates increase confidence in upcoming data, says Piper Jaffray
After Alnylam presented new data on its Phase II study of patisiran in patients with Familial Amyloidotic Polyneuropathy, PiperJaffray says that the data increases its optimism about the outlook for a Phase III trial of the treatment in 2016. The firm keeps an Overweight rating on the stock.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
16:18 EDTALNYAlnylam weakness a buying opportunity, says Deutsche Bank
Deutsche Bank said Alnylam's Phase 1 AT-3 conference presentation update was positive, as expected, supporting safety and efficacy. The firm's analyst said weakness could be due to fast money selling and recommends buying shares on weakness.
14:31 EDTALNYAlnylam reports new positive clinical data for ALN-AT3
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use